• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Astrana Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    9/11/25 7:20:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary
    Get the next $ASTH alert in real time by email
    false 0001083446 0001083446 2025-07-01 2025-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K/A

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): July 1, 2025

     

    ASTRANA HEALTH, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware 001-37392 95-4472349
    (State or Other Jurisdiction (Commission (I.R.S. Employer
    of Incorporation) File Number) Identification No.)

     

    1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

    (Address of Principal Executive Offices) (Zip Code)

     

    (626) 282-0288

    Registrant’s Telephone Number, Including Area Code

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

      

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 par value per share   ASTH   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

      

     

     

       

     

     

    Explanatory Note

     

    On July 2, 2025, Astrana Health, Inc. (the “Company) filed a Current Report on Form 8-K (the “Initial Form 8-K”) to report that it had completed the acquisition of all of the outstanding equity interests of Prospect Health Plan, Inc. and Alta Newport Hospital, LLC (d/b/a Foothill Regional Medical Center), and substantially all the assets of certain direct and indirect subsidiaries of PHP Holdings, LLC (“PHPH”), pursuant to the Asset and Equity Purchase Agreement, dated November 8, 2024, by and among the Company and certain direct and indirect subsidiaries party thereto, PHPH, PHS Holdings, LLC, Prospect Intermediate Holdings, LLC, Prospect Provider Group RI, LLC, certain other related entities party thereto and Prospect Medical Holdings, Inc., as Seller Representative (such acquisition, the “Transaction” and such acquired entities and assets, the “Acquired Business”).

     

    This Current Report on Form 8-K/A amends the Initial Form 8-K to include the audited financial statements of business acquired required by Item 9.01(a) and unaudited pro forma consolidated financial information required by Item 9.01(b) of Form 8-K and to update certain disclosures under Item 9.01(a) and (b) of the Initial Form 8-K. Such information should be read in conjunction with the Initial Form 8-K. Except as provided herein, the disclosures made in the Initial Form 8-K remain unchanged.

     

    Item 9.01Financial Statements and Exhibits.

     

    (a) Financial Statements of Business Acquired.

     

    The audited financial statements of the Acquired Business as of and for the fiscal years ended September 30, 2024 and 2023, and the related Report of Independent Auditors, and the unaudited financial statements of the Acquired Business as of and for the six months ended March 31, 2025 and for the six months ended March 31, 2024, including, in each case, the accompanying notes, are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K/A and are incorporated herein by reference.

     

    (b) Pro Forma Financial Information.

     

    The unaudited pro forma condensed combined balance sheet of the Company as of March 31, 2025 and the unaudited pro forma condensed combined statements of operations of the Company for the fiscal year ended December 31, 2024 and for the three months ended March 31, 2025 (collectively, the “Unaudited Pro Forma Financial Information”) are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and are incorporated herein by reference. The Unaudited Pro Forma Financial Statements give effect to the Transaction and related transactions.

     

    The Unaudited Pro Forma Financial Information is presented for illustrative purposes only and is not intended to represent or be indicative of the Company’s consolidated results of operations or financial position that would have been reported had the Transaction and related transactions been completed as of the dates presented in the Unaudited Pro Forma Financial Information. The Unaudited Pro Forma Financial Information should not be taken as a representation of the Company’s future consolidated results of operations or financial condition. The pro forma adjustments in the Unaudited Pro Forma Financial Information are based on available information and certain assumptions that management believes are reasonable under the circumstances.

     

     

     

     

    (d) Exhibits.

     

    Exhibit
    No.
      Description
    23.1   Consent of BDO USA, P.C.
    99.1   Audited financial statements of the Acquired Business as of and for the fiscal years ended September 30, 2024 and 2023 and the related Report of Independent Auditors, including the notes thereto.
    99.2   Unaudited financial statements of the Acquired Business as of and for the six months ended March 31, 2025 and for the six months ended March 31, 2024, including the notes thereto.
    99.3   Unaudited pro forma condensed combined balance sheet of Astrana Health, Inc. as of March 31, 2025 and unaudited pro forma condensed combined statements of operations of Astrana Health, Inc. for the fiscal year ended December 31, 2024 and for the three months ended March 31, 2025.
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ASTRANA HEALTH, INC.
       
    Date: September 11, 2025 By: /s/ Brandon K. Sim
      Name: Brandon K. Sim
      Title: Chief Executive Officer and President

     

     

    Get the next $ASTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTH

    DatePrice TargetRatingAnalyst
    12/12/2025$28.00Buy
    Needham
    4/1/2025$36.00Equal Weight
    Barclays
    10/14/2024$66.00Buy
    TD Cowen
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    7/11/2024$44.00 → $50.00Hold → Buy
    Truist
    5/30/2024$54.00Outperform
    Robert W. Baird
    More analyst ratings

    $ASTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lam Thomas S. covered exercise/tax liability with 9,266 shares, decreasing direct ownership by 2% to 423,990 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    3/9/26 4:16:36 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Chief Medical Officer Kumar Dinesh M. covered exercise/tax liability with 1,697 shares, decreasing direct ownership by 0.84% to 200,335 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    3/9/26 4:16:06 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    COO and CFO Basho Chandan covered exercise/tax liability with 1,240 shares, decreasing direct ownership by 0.71% to 173,727 units (SEC Form 4)

    4 - Astrana Health, Inc. (0001083446) (Issuer)

    3/9/26 4:15:24 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ASTH
    SEC Filings

    View All

    Needham initiated coverage on Astrana Health with a new price target

    Needham initiated coverage of Astrana Health with a rating of Buy and set a new price target of $28.00

    12/12/25 8:48:58 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Barclays initiated coverage on Astrana Health with a new price target

    Barclays initiated coverage of Astrana Health with a rating of Equal Weight and set a new price target of $36.00

    4/1/25 7:41:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    TD Cowen initiated coverage on Astrana Health with a new price target

    TD Cowen initiated coverage of Astrana Health with a rating of Buy and set a new price target of $66.00

    10/14/24 7:24:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    SEC Form 10-K filed by Astrana Health Inc.

    10-K - Astrana Health, Inc. (0001083446) (Filer)

    3/12/26 8:11:04 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Astrana Health, Inc. (0001083446) (Filer)

    3/4/26 7:30:49 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    SEC Form NT 10-K filed by Astrana Health Inc.

    NT 10-K - Astrana Health, Inc. (0001083446) (Filer)

    3/2/26 8:45:24 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Foothill Regional Medical Center Receives 2026 Patient Safety Excellence Award™ from Healthgrades

    Recognition places Foothill Regional among the top 5% in the nation for patient safety TUSTIN, Calif., March 10, 2026 /PRNewswire/ -- Foothill Regional Medical Center, part of Astrana Health, Inc. (NASDAQ:ASTH), has been recognized as a 2026 Patient Safety Excellence Award™ recipient by Healthgrades, the nation's leading resource Americans use when searching for a hospital or doctor. Foothill Regional has received the Patient Safety Excellence Award™ four consecutive years (2023-2026). In addition to this patient safety recognition, Foothill Regional has earned several distingui

    3/11/26 8:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. to Participate in Upcoming Investor Conferences

    ALHAMBRA, Calif., March 3, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership is participating in the following upcoming investor conferences: The TD Cowen 45th Annual Health Care Conference, being held in Boston on Wednesday, March 4, 2026, including a fireside chat at 9:10am ET.The Jefferies Value-Based Healthca

    3/3/26 5:00:00 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results

    Company to Host Conference Call on Monday, March 2, 2026, at 5:30 a.m. PT/8:30 a.m. ETReports total revenue for the year ended of $3,181.8 million, up 56% year-over-year, and at the higher end of guidanceReports adjusted EBITDA for the year ended of $205.4 million and free cash flow(1) of $104.5 millionALHAMBRA, Calif., March 2, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading physician-centric, technology-powered, risk-bearing healthcare management company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial result

    3/2/26 7:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    $ASTH
    Financials

    Live finance-specific insights

    View All

    Astrana Health, Inc. Reports Fourth Quarter and Year End 2025 Results

    Company to Host Conference Call on Monday, March 2, 2026, at 5:30 a.m. PT/8:30 a.m. ETReports total revenue for the year ended of $3,181.8 million, up 56% year-over-year, and at the higher end of guidanceReports adjusted EBITDA for the year ended of $205.4 million and free cash flow(1) of $104.5 millionALHAMBRA, Calif., March 2, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading physician-centric, technology-powered, risk-bearing healthcare management company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial result

    3/2/26 7:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Schedules 2025 Fourth Quarter and Year-End Financial Results Release and Conference Call

    ALHAMBRA, Calif., Jan. 26, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ:ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025, before the open of the stock market on Monday, March 2, 2026. The Company will discuss those results on a conference call at 5:30 a.m. PT/8:30 a.m. ET that same day.

    1/26/26 8:00:00 AM ET
    $ASTH
    Professional Services
    Consumer Discretionary

    Astrana Health, Inc. Reports Third Quarter 2025 Results

    Company to Host Conference Call on Thursday, November 6, 2025, at 2:30 p.m. PT/5:30 p.m. ET Reports total revenue of $956.0 million, up 100% year-over-year, and at the higher end of guidanceReports adjusted EBITDA of $68.5 million, at the higher end of guidanceCloses Prospect Health acquisition where standalone third quarter performance exceeded expectationsContinuing to control medical costs well; reiterating full-year trend expectationsUpdates full-year 2025 guidance to account for full-risk contract delays unrelated to core performanceALHAMBRA, Calif., Nov. 6, 2025 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (

    11/6/25 4:05:00 PM ET
    $ASTH
    Professional Services
    Consumer Discretionary